Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 6/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.40 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL433952 | 0.78 | CYP1A2 (0.46) | MAOACYP1A2KDM4ETP53MAPT | |
| SCHEMBL9923790 | 0.77 | KDM4E (0.50) | MAOAKDM4EMAPTRECQLHSD17B10 | |
| SCHEMBL2274000 | 0.76 | MAOA (0.41) | MAOAKDM4ETP53MAPTALOX15 | |
| SCHEMBL28382544 | 0.76 | ATM (0.47) | MAOACYP1A2KDM4ETP53MAPT | |
| SCHEMBL30176877 | 0.76 | ATM (0.47) | MAOACYP1A2KDM4ETP53MAPT | |
| SCHEMBL20125051 | 0.75 | NQO1 (0.42) | CYP1A2KDM4EMAPTHSD17B10POLB | |
| SCHEMBL8286028 | 0.75 | AHR (0.42) | CYP1A2CYP1A1CYP1B1 | |
| SCHEMBL12778694 | 0.75 | CYP1A2 (0.43) | MAOACYP1A2KDM4ETP53MAPT | |
| SCHEMBL5035815 | 0.75 | CYP1A1 (0.40) | MAOACYP1A2TP53MAPTRECQL | |
| SCHEMBL12728518 | 0.75 | CYP1A1 (0.40) | CYP1A2SMN1; SMN2CYP1A1CYP1B1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040231067-A1 | Dyeing composition comprising a cationic tertiary para-phenylenediamine and heterocyclic coupler, methods and uses | L'OREAL (FR) | 2004-11-25 | — | — | US | claimed |
| EP-1428510-A1 | Dyeing composition comprising a tertiary paraphenylenediamine containing a pyrrolidine, and a heterocyclic coupler or a hydroxybenzamide ; method and use | L'OREAL (FR) | 2004-06-16 | — | — | EP | claimed |
| EP-0506549-B1 | Dyeing composition for keratinous fibers containing oxidation dye precursors and hydroxybenzofurans as couplers and dyeing process making use of such a composition | OREAL (FR) | 1995-10-18 | — | — | EP | claimed |
| US-5203875-A | Hair dyes also using ortho- and para-phenylenediamines or aminophenols; colorfastness; washfastness; perspiration resistance | L'OREAL (FR) | 1993-04-20 | — | — | US | claimed |
| US-10202360-B2 | Therapeutic compounds | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| EP-2182914-B1 | COMPOSITION OXIDATION COLOURING OF KERATINIC FIBRES, CONTAINING A CATIONIC CELLULOSE ETHER, A METASILICATE AND OXIDATION DYES, METHOD FOR OXIDATION COLOURING AND USES THEREOF | L'ORÉAL (FR) | 2017-11-08 | — | — | EP | disclosed |
| US-20170298040-A1 | THERAPEUTIC COMPOUNDS | CELGENE QUANTICEL RESEARCH, INC. | 2017-10-19 | — | — | US | disclosed |
| US-20170298040-A1 | THERAPEUTIC COMPOUNDS | CELGENE QUANTICEL RESEARCH, INC. | 2017-10-19 | — | — | US | disclosed |
| EP-2175830-B1 | COMPOSITION FOR OXIDATION DYEING KERATIN FIBRES COMPRISING A CATIONIC CELLULOSE ETHER, A WEAKLY OXYETHYLENATED SORBITAN FATTY ACID ESTER AND OXIDATION DYES | ORÉAL L (FR) | 2015-09-30 | — | — | EP | disclosed |
| US-8273897-B2 | Method for producing 2,2-difluoroethylamine derivative by amide hydrogenation | BAYER CROPSCIENCE AG (DE) | 2012-09-25 | — | — | US | disclosed |
| US-8043385-B2 | Composition oxidation colouring of keratinic fibres, containing a cationic cellulose ether, a metasilicate and oxidation dyes, method for oxidation colouring and uses thereof | L'OREAL S.A. (FR) | 2011-10-25 | — | — | US | disclosed |
| US-8002847-B2 | Composition for oxidation dyeing keratin fibres comprising a cationic cellulose ether, a weakly oxyethylenated sorbitan fatty acid ester and oxidation dyes | L 'OREAL S.A. (FR) | 2011-08-23 | — | — | US | disclosed |
| US-20030232833-A1 | Benzofuran derivatives | ELI LILLY AND COMPANY | 2003-12-18 | — | — | US | disclosed |
| EP-1246822-A1 | BENZOFURAN DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-10-09 | — | — | EP | disclosed |
| WO-2001046177-A1 | BENZOFURAN DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-06-28 | — | — | WO | disclosed |
| US-5254595-A | Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them | ELF SANOFI (FR) | 1993-10-19 | — | — | US | disclosed |
| US-5203875-A | Hair dyes also using ortho- and para-phenylenediamines or aminophenols; colorfastness; washfastness; perspiration resistance | L'OREAL (FR) | 1993-04-20 | — | — | US | disclosed |
| EP-0054924-B1 | PHARMACEUTICAL COMPOUNDS, THEIR PREPARATION AND USE | THE WELLCOME FOUNDATION LIMITED (GB) | 1986-08-06 | — | — | EP | disclosed |
| US-4535183-A | PALLIATION OF SICKLE CELL ANEMIA, RESPIRATORY DISORDERS, HYPOXIA, RADIOSENSITIZATION OF TUMORS | BURROUGHS WELLCOME CO. (US) | 1985-08-13 | — | — | US | disclosed |
| EP-0054924-A2 | Pharmaceutical compounds, their preparation and use | THE WELLCOME FOUNDATION LIMITED (GB) | 1982-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202360-B2 | Therapeutic compounds | EP300, BRDT, BRPF3 | MAOA 3998/4885CYP1A2 4847/4885KDM4E 160/4885 |
| US-20030232833-A1 | Benzofuran derivatives | BRD1, BPTF, HTR1F | MAOA 79/4885CYP1A2 162/4885KDM4E 588/4885 |
| US-20170298040-A1 | THERAPEUTIC COMPOUNDS | EP300, BRDT, BRPF3 | MAOA 3998/4885CYP1A2 4847/4885KDM4E 160/4885 |
| US-20040231067-A1 | Dyeing composition comprising a cationic tertiary para-phenylenediamine and heterocyclic coupler, methods and uses | KRT18, CDC73, PYCR1 | MAOA 1216/4885CYP1A2 1508/4885KDM4E 1620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.